MicroPort® Announces Multiple Results from the TARGET Clinical Study on Firehawk® Stent at TCT 2021

Orlando, USA, 17 November 2021 — MicroPort Scientific Corporation (MicroPort®) recently shared the latest progress of the TARGET series clinical trials for the Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®) at the 2021 Transcatheter Cardiovascular Therapy Congress (TCT 2021). The congress, held in Orlando, USA, was chaired by Prof. Martin B. Leon, Founder of the congress and Chairman Emeritus of Cardiovascular Research Foundation, who emphasized the value of the clinical experience of Firehawk® in Europe and China, and announced the start of the clinical study of Firehawk® in the US.

At the event, which was attended by world-leading interventional cardiologists, Prof. Alexandra Lansky, from the Yale University School of Medicine, spoke positively on Firehawk®, commenting that the latest four-year follow-up results of the TARGET All Comers (TARGET AC), as well as the results of its diabetes subgroup, showed that the Firehawk® demonstrated sustained efficacy and safety in an all-comers population (ID-TLR 4.6% vs. 5.7%, p=0.32; in-stent thrombosis 2.3% vs. 2.9%, p=0.44). Among those patients who discontinued the dual antiplatelet therapy (DAPT) in two years, the Firehawk® stent performed better in terms of safety (TV-MI and ID-TLR tend to be lower) compared with competing products.

The Firehawk® stent shows safety and efficacy in standard risk populations in the TARGET I and the TARGET II studies, according to Prof. Leon of Columbia University Medical Center. He stated that, according to the results in complex patient populations—such as those studied in the TARGET AC and TARGET CTO programs—Firehawk® also has comparable safety and efficacy to competing products.

Prof. Leon noted, "In the near future, there will be 27 global TARGET Global databases of 35,600 patients with a range of complex lesions. It will be one of the largest bodies of evidence in terms of the number of patients included worldwide.”

In addition, Prof. Andreas Baumbach from the Barts Heart Centre at St. Bartholomew's Hospital spoke highly of the Firehawk® stent, commenting, "Firehawk® features good visibility and is well suited for bifurcation lesions.” He expressed his excitement to see the results of the TARGET AC 5-year study, which will be presented at EuroPCR 2022.

MicroPort® has a strong focus on clinical studies to verify the effectiveness and safety of its products through strong clinical evidence. In the future, it will continue to advance the TARGET global series of clinical studies to bring medical solutions to patients around the world with the most advanced technologies.

About Shanghai MicroPort Medical (Group) Co., Ltd.

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), is a subsidiary of MicroPort Scientific Corporation (Group) Co., Ltd. (stock code: 00853.HK). Founded in 1998, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with high-end medical devices and integrated solutions.